Form 4: Astria Director Cashes Out Options Post-BioCryst Merger

Astria Therapeutics Director Sunil Agarwal cashed out all in-the-money stock options following the company's merger with BioCryst Pharmaceuticals' subsidiary.

Summary

• Astria Therapeutics, Inc. merged with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc., effective January 23, 2026.
• Astria Therapeutics, Inc. survived the merger and became a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Director Sunil Agarwal's in-the-money stock options became fully vested and exercisable, then were canceled in exchange for a cash payment.
• The cash payment for each option was calculated as the total number of shares subject to the option multiplied by the difference between $13.00 and the option's exercise price.
• Options for 28,200 shares with an exercise price of $11.4 were cashed out.
• Options for 26,550 shares with an exercise price of $5.79 were cashed out.
• Sunil Agarwal no longer beneficially owns derivative securities in Astria Therapeutics, Inc. following these transactions.

Sentiment

Score: 7

Explanation: The filing reports the expected cash-out of director options following a merger, which is a standard procedural outcome. It reflects the successful completion of the merger for Astria Therapeutics, Inc. into BioCryst Pharmaceuticals, Inc., providing a clear resolution for the company and its insiders.

Positives

• Director Agarwal received cash for his in-the-money options, indicating a positive financial outcome for his personal holdings related to the merger.
• The completion of the merger provides a definitive outcome for Astria Therapeutics, Inc. and its stakeholders.

Negatives

• Astria Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Director Agarwal is no longer subject to Section 16 reporting obligations, suggesting a change in his directorship or a reduced role post-merger.

Future Outlook

NA

Industry Context

NA

Management Changes

Stakeholder Impact

• Shareholders of Astria Therapeutics, Inc. would have received consideration as per the merger agreement, which is implied by the option payout structure.
• Director Sunil Agarwal received a cash payment for his vested in-the-money options, indicating a financial benefit from the merger.

Key Dates

Keywords

Astria Therapeutics, BioCryst Pharmaceuticals, Merger, Stock Options, Insider Transaction, Form 4, ATXS, Sunil Agarwal